secwatch.observer — SEC 8-K summary
======================================

Issuer:     PHIBRO ANIMAL HEALTH CORP (PAHC)
CIK:        0001069899
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001104659-25-107064
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phibro Q1 net sales up 40% to $363.9M; raises FY2026 adjusted EBITDA guidance to $230-240M
--------------------------------------------------------------------------------

- Net sales $363.9M (+40% YoY); net income $26.5M ($0.65 diluted EPS) vs $7.0M ($0.17) prior year.
- Adjusted diluted EPS $0.73 (doubled from $0.35); adjusted EBITDA $61.9M (+$31.2M YoY).
- Animal Health sales rose 55% to $283.5M, driven by acquired MFA portfolio (+$80.5M incremental).
- FY2026 guidance: Adjusted EBITDA raised to $230-240M (28% growth); net sales reaffirmed $1.43-1.48B.
- Company launched Restoris™ dental gel for dogs; annual meeting reelected all director nominees and approved say-on-pay every 3 years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069899/000110465925107064/0001104659-25-107064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069899/000110465925107064/pahc-20251104x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-107064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer